Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

Protocol to Obtain Blood and Bone Marrow Samples for Myeloma Research

This study has been terminated.
(Unable to fill cohort)
Information provided by (Responsible Party):
Dartmouth-Hitchcock Medical Center Identifier:
First received: April 12, 2010
Last updated: May 23, 2016
Last verified: May 2016
The purpose of this study is to collect a blood or bone marrow sample from patients with multiple myeloma and from volunteers without myeloma.

Multiple Myeloma

Study Type: Observational
Study Design: Observational Model: Cohort
Time Perspective: Prospective
Official Title: Evaluation of Immune Parameters and Function in Multiple Myeloma Patients and Healthy Individuals' Blood and Marrow Samples

Resource links provided by NLM:

Further study details as provided by Dartmouth-Hitchcock Medical Center:

Primary Outcome Measures:
  • Cancer cell response to molecular testing of killing cell parts. [ Time Frame: 2 Years ]
    This myeloma specific killing may help identify mechanisms, in vitro, of killing myeloma cells for the future use in clinical trials.

Biospecimen Retention:   Samples With DNA
15mL of peripheral blood 10mL of bone marrow aspirate

Estimated Enrollment: 75
Study Start Date: August 2010
Study Completion Date: December 2014
Primary Completion Date: December 2014 (Final data collection date for primary outcome measure)
Healthy Volunteers
Healthy volunteers who have agreed to have a bone marrow and/or blood harvest as part of a donation to a transplant recipient.
Patients with multiple myeloma
Patients undergoing routine blood draw and bone marrow aspirates as part of their ongoing follow-up care for myeloma at the Norris Cotton Cancer Center of DHMC.

Detailed Description:
The blood and bone marrow samples will be used in the laboratory to perform focused studies on multiple myeloma.

Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Sampling Method:   Non-Probability Sample
Study Population
Patients at Dartmouth-Hitchcock Medical Center's Norris Cotton Cancer Center

Inclusion Criteria:

  • Participant population is multiple myeloma patients over the age of 18 who are undergoing a scheduled bone marrow collection and/or blood drawing procedure as part of their routine treatment or follow up, and healthy volunteers over the age of 18 who have agreed to have a bone marrow and/or blood harvest as part of a donation to a transplant recipient.

Exclusion Criteria:

  • Patients, who in the opinion of their physician, would be adversely affected by removal of an extra15ml of blood and /or an extra 10ml of bone marrow.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01382615

United States, New Hampshire
Dartmouth-Hitchcock Medical Center
Lebanon, New Hampshire, United States, 03756
Sponsors and Collaborators
Dartmouth-Hitchcock Medical Center
Principal Investigator: Kenneth Meehan, MD Dartmouth-Hitchcock Medical Center
  More Information

Responsible Party: Dartmouth-Hitchcock Medical Center Identifier: NCT01382615     History of Changes
Other Study ID Numbers: D1029
Study First Received: April 12, 2010
Last Updated: May 23, 2016

Keywords provided by Dartmouth-Hitchcock Medical Center:
Multiple Myeloma

Additional relevant MeSH terms:
Multiple Myeloma
Neoplasms, Plasma Cell
Neoplasms by Histologic Type
Hemostatic Disorders
Vascular Diseases
Cardiovascular Diseases
Blood Protein Disorders
Hematologic Diseases
Hemorrhagic Disorders
Lymphoproliferative Disorders
Immunoproliferative Disorders
Immune System Diseases processed this record on April 28, 2017